FKBP5 and Anxiety: These agents have a promising profile of effects, with preclinical experiments in rodents showing that FKBP51 antagonists improve stress-coping behaviour and reduce anxiety when given systemically or directly into relevant brain regions such as the amygdala [13, 22].